Applied Clinical Trials
Arthur L. Caplan, Ph.D., chair of the University of Pennsylvania's Department of Medical Ethics, expressed his frank views about issues that are ailing the drug industry today during his DIA Keynote Address in mid-June.
Arthur L. Caplan, Ph.D., chair of the University of Pennsylvania's Department of Medical Ethics, expressed his frank views about issues that are ailing the drug industry today during his DIA Keynote Address in mid-June.
He began by recounting the circumstances surrounding the well-known 1999 death of Jesse Gelsinger, a subject in a gene therapy trial of a drug to treat OTC deficiency-a rare metabolic disease that prevents the body from properly processing protein and which is frequently fatal in infants.
Attendees exchanging ideas at DIAs 40th Annual Meeting, held at the Washington Convention Center in DC.
Caplan conceded that there were problems connected with the University of Pennsylvania trial, even though two separate IRBs as well as the NIH were involved. He also emphasized that although both the lead scientist and the university had possible conflicts of interests, they were nonetheless motivated to "save babies and do good."
Pointing to such issues as poor informed consent, ineffective peer review, and conflicts of interest, Caplan suggested several steps to help fix a " broken system ."
First, he says, the industry must do a better job collecting basic data on human subjects and adhering to accepted GCP protocols during clinical trials. "We have better data on animals than we have on people," Caplan lamented.
Attendees exchanging ideas at DIA's 40th Annual Meeting, held at the Washington Convention Center in DC.
Second, he advocates splitting the functions of the IRBs and DSMBs. Ethics committees, he argues, are overwhelmed and should focus on monitoring informed consent while the DSMBs should oversee data compliance. To better utilize IRB resources, Caplan favors increased audits at pivotal trials and fewer, more random audits in low-risk studies. When problems are uncovered in less critical trials, however, he says there should be heavier sanctions levied.
Third, Caplan favors creation of a central registry of adverse events: "Disclosure is great; transparency is greater."
Attendees exchanging ideas at DIAs 40th Annual Meeting, held at the Washington Convention Center in DC.
Finally, he believes a flexible, worldwide compensation policy for payouts to those affected by adverse events would help, cautioning, " One size does not fit all ."
It would be unrealistic to believe Caplan's solutions will be implemented in the near term. Nevertheless, these issues provide for provocative discussion in the ongoing dialogue over stronger subject protections in clinical trials.-Rob Davidson
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.